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Introduction {#sec1}
============

Leukocytes exit the blood by undergoing extensive interactions with endothelial cells. This sequence of events is known as the leukocyte adhesion cascade ([@bib6], [@bib20], [@bib27], [@bib38], [@bib42], [@bib43]). Circulating leukocytes first tether along endothelial cells by engaging P-selectin glycoprotein ligand-1 (PSGL-1) with E- and P-selectin presented on the endothelium. This process brings the cells in closer proximity to the vessel wall and slows them down to roll along endothelial cells, using PSGL-1 as well as L-selectin to interact with endothelial selectins. During this step, leukocytes come in contact with chemokines presented on the endothelial cell surface. Chemokines engage chemokine receptors on leukocytes, leading to Gαi-mediated inside-out signaling of integrins. Integrins extend into a high-affinity conformation and mediate the firm adhesion of leukocytes. Lymphocyte function-associated antigen-1 (LFA-1) (CD11a/CD18 or αLβ2 integrin), macrophage-1 antigen (Mac-1) (CD11b/CD18 or αMβ2 integrin), and very late antigen-4 (VLA-4) (CD49d/CD29 or α4β1 integrin) play a major role in this step and interact with members of the immunoglobulin superfamily on endothelial cells, primarily intercellular adhesion molecule-1 (ICAM-1), ICAM-2, and vascular cell adhesion molecule-1 (VCAM-1). In the final step, adherent leukocytes crawl along the vessel wall, probe for adequate sites for crossing the endothelium, and emigrate from the vascular lumen into the parenchyma in a process termed transmigration.

The requirement of specific molecules in the leukocyte emigration process is highly dependent on the tissue context and the leukocyte subset involved ([@bib36]). Interactions between receptor-ligand pairs of pro-migratory molecules governing the subset-specific migration process of leukocytes to specific organs have been referred to as a homing code ([@bib24], [@bib32], [@bib38]). Although some of these molecular binding partners are known and have been discussed above, the trafficking requirements of many leukocyte subsets are unclear. This is particularly true for the steady state because leukocyte infiltration into organs has mostly been studied in inflammatory scenarios.

Recent data point to the influence of time of day on the number of leukocytes present in the circulation ([@bib7], [@bib11], [@bib28], [@bib33], [@bib37], [@bib41]). These circadian rhythms, occurring within a period of approximately 24 h, are critical in aligning the body to the usual recurring cycles of the environment ([@bib2], [@bib8], [@bib9], [@bib18], [@bib23], [@bib35], [@bib34]). The number of leukocytes circulating in blood is largely dependent on two factors: mobilization into blood from organs such as bone marrow, which increases cellularity in blood (input); and emigration from blood into organs, decreasing cellularity in blood (output). Here, we investigated the hypothesis that leukocyte subsets migrate to organs at specific times of the day. By employing this diurnal rhythmicity as a functional screening tool in combination with a systematic approach of adoptive transfer and homing assays, we detected a time-resolved code of pro-migratory factors for the specific migration behavior of leukocyte subsets to organs. Lineage-specific genetic ablation of the circadian clock demonstrated that endothelial-cell- and leukocyte-autonomous oscillations are critical in these processes. These rhythms are relevant in inflammation and determine leukemic tumor burden at specific times. Human primary leukocytes exhibit a similar time-resolved code of pro-migratory factors. The circadian patterns of expression of pro-migratory factors defined here present a resource for the further exploration of how the immune system has adapted to the recurring cycle of the environment and to the relevance of this adaptation in health and disease.

Results {#sec2}
=======

Rhythmic Emigration of Leukocyte Subsets from Blood {#sec2.1}
---------------------------------------------------

Circulating white blood cell (WBC) counts oscillate in murine blood such that they exhibit a peak 5 hr after the onset of light (also known as Zeitgeber time \[ZT\] 5, i.e., 5 hr after lights on \[12 p.m.\] in a 12 hr/12 hr light/dark environment) and a trough in the evening (ZT13 or 8 p.m., 1 hr after lights off) ([Figure 1](#fig1){ref-type="fig"}A). Numbers of neutrophils, B cells, CD4 and CD8 T cells, natural killer (NK) cells, NK T cells, eosinophils, and inflammatory and non-inflammatory monocytes showed similar peaks and troughs with a 2- to 7-fold change in numbers between the peak and trough depending on the subset ([Figure 1](#fig1){ref-type="fig"}A, [Figure S1](#mmc1){ref-type="supplementary-material"}A, and data not shown). We investigated whether a rhythmic leukocyte emigration process could explain the observed oscillations in blood. As an initial screen, we performed "negative" homing assays, where 1 hr after adoptively transferring leukocytes intravenously (i.v.), we quantified the number of transferred cells remaining in the blood to assess emigration of cells across the whole organism. To additionally investigate the influence of a rhythmic microenvironment in this process, we harvested donor cells at one time and transferred them simultaneously into recipients that were kept in shifted light cycles. We saw a clear diurnal rhythm given that the number of labeled donor cells remaining in the blood after transfer was lowest in an evening environment (ZT13) and highest in the morning (ZT1) for all investigated subsets ([Figure 1](#fig1){ref-type="fig"}B and [Figure S1](#mmc1){ref-type="supplementary-material"}B). This demonstrated that in the evening more cells had left the blood, for example, by migrating into tissues or by firm contact with the vasculature, both of which effectively removed them from the circulation. Furthermore, it demonstrated a strong influence of rhythmicity in the microenvironment on leukocyte recruitment and numbers in blood in general. We next assessed the role of rhythmicity in leukocytes in this process. This time, donor cells were harvested from mice kept in shifted light cycles and simultaneously injected into recipient mice at one time of the day. In this scenario as well, "evening" cells showed the highest emigration behavior, and "morning" cells generally showed the lowest ([Figure 1](#fig1){ref-type="fig"}C). We confirmed these observations by performing reciprocal emigration assays where "morning" or "evening" cells were co-injected into "morning" or "evening" recipients, respectively, with differential color labeling ([Figure S1](#mmc1){ref-type="supplementary-material"}C). These data thus demonstrated that both microenvironment and leukocytes co-contribute to rhythmic leukocyte exit from the circulation, a broad phenomenon that peaks in the evening for all subsets investigated.Figure 1Rhythmic Recruitment Is Governed by Both Microenvironment and Leukocytes(A) Total leukocyte and leukocyte subset counts over 24 hr. Zeitgeber time (ZT, time after light onset) 1 is double plotted to facilitate viewing (n = 9--62 mice; one-way ANOVA). WBC, white blood cell; NK, natural killer; IM, inflammatory monocyte; NIM, non-inflammatory monocyte.(B) Diagram of adoptive-transfer assay with rhythmic recipients. Shown are numbers of adoptively transferred donor cells present in the blood of recipient mice 1 hr after transfer over 24 hr. Data are normalized to ZT5 levels (n = 3--25 mice; one-way ANOVA).(C) Diagram of adoptive-transfer assay with rhythmic donors. Shown are numbers of adoptively transferred donor cells present in blood of recipient mice 1 hr after transfer over 24 hr. Data are normalized to ZT5 levels (n = 3--17 mice; one-way ANOVA).^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. All data are represented as mean ± SEM. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Tissue-Specific Oscillations in Endothelial Cell Adhesion Molecules {#sec2.2}
-------------------------------------------------------------------

Because the microenvironment is a strong driver of rhythmic leukocyte emigration from blood ([Figure 1](#fig1){ref-type="fig"}B), we performed a screen of multiple organs for oscillatory expression of adhesion molecules on endothelial cells, the initial points of contacts for leukocytes in the emigration process. To achieve this, we harvested multiple organs (thymus, spleen, lymph node, liver, skin, gut, lung, and Peyer's patches) from mice over six time points of the day. We then performed quantitative fluorescence microscopy imaging assays on sections from each organ, which allowed us to minimize variability and compare expression patterns across tissues within the same mice at the same time. This approach yielded a highly tissue-specific temporal expression map for endothelial cell adhesion molecules ([Figure 2](#fig2){ref-type="fig"}A and [Table S1](#mmc2){ref-type="supplementary-material"}). Integrating the profiles from all expressed molecules across all organs over time revealed a peak in expression in the evening ([Figure 2](#fig2){ref-type="fig"}B). This indicated that endothelial cells within the body (or at least within the eight organs assessed as proxy) had a distinctly higher leukocyte recruitment capacity at this time. This was in line with the negative homing data, which represented highest leukocyte emigration in the evening from blood across the whole organism ([Figure 1](#fig1){ref-type="fig"}B). Specifically, ICAM-1 was expressed in every vascular bed analyzed, VCAM-1 was expressed in all but the skin, and both exhibited peaks in expression in the evening ([Figure 2](#fig2){ref-type="fig"}C). ICAM-2 was expressed in all organs except spleen and skin, whereas P-selectin was expressed in all investigated organs but the liver. Expression for both molecules peaked in the evening; however, this was not statistically significant ([Figure S2](#mmc1){ref-type="supplementary-material"}A). In functional assays, we next focused on the molecules that showed oscillations and robust expression levels across organs because these molecules were likely to be critical in mediating rhythmic homing for many of the investigated subsets. Indeed, chronopharmacological blockade with an antibody directed against VCAM-1 in the morning or at night resulted in increased numbers of adoptively transferred cells in the circulation, signifying reduced tissue homing. This additionally ablated their day-night oscillation ([Figures 2](#fig2){ref-type="fig"}D and 2E). Blockade with an anti-ICAM-1 antibody increased numbers of neutrophils, T cells, eosinophils, and non-inflammatory monocytes and ablated their rhythmicity but had no effect on inflammatory monocytes ([Figures 2](#fig2){ref-type="fig"}D and 2E). This was confirmed genetically with *Icam1*-deficient recipients ([Figures 2](#fig2){ref-type="fig"}F and 2G). Blocking of ICAM-2, E-selectin, or P-selectin, on the other hand, had little or no effect on leukocyte cellularity or oscillations in blood ([Figure 2](#fig2){ref-type="fig"}D). Importantly, we generally observed a much more pronounced blocking effect when antibodies were administered in the evening than when they were administered in the morning for both adoptively transferred and endogenous leukocyte populations ([Figure 2](#fig2){ref-type="fig"}E and [Figure S2](#mmc1){ref-type="supplementary-material"}B). This established the functional importance of time of day and an oscillatory expression of endothelial cell adhesion molecules for the emigration of leukocyte subsets from blood.Figure 2Tissue-Specific Oscillations in Endothelial Cell Adhesion Molecules(A) Map of rhythmic protein expression of endothelial cell-adhesion molecules of various organs (n = 3--6 mice with 6 time points measured each; one-way ANOVA).(B) Integration of all expressed molecules over all organs across the day (n = 3--6 mice with 6 time points measured each; one-way ANOVA).(C) Integration of ICAM-1 and VCAM-1 expression over all organs across the day (n = 3--6 mice with 6 time points measured each; one-way ANOVA).(D) Adoptive transfer of donor cells to recipients treated with functional blocking antibodies directed against the indicated molecules at ZT1 and ZT13. Results are presented as percentages of injected cells (n = 4--12 mice; one-way ANOVA followed by Dunnett comparison to control groups and unpaired Student's t test for comparisons between ZT1 and ZT13 groups).(E) Fold change of donor cells remaining in recipient blood at ZT1 and ZT13 after anti-VCAM-1 or anti-ICAM-1 antibody treatment, respectively, in comparison with numbers of isotype antibody controls (n = 7--11 mice; unpaired Student's t test).(F) Adoptive transfer of donor cells to *Icam1*^−/−^ recipients at ZT1 and ZT13 (n = 6--8 mice; unpaired Student's t test).(G) Endogenous blood leukocyte numbers in *Icam1*^−/−^ mice at ZT1 and ZT13 (n = 6--8 mice; unpaired Student's t test).^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001; ^\#,\ \#\#,\ \#\#\#,\ \#\#\#\#^ indicate significance levels analogous to those of control groups. All data are represented as mean ± SEM. ns, not significant; MFI, mean fluorescence intensity. See also [Figure S2](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}.

Leukocyte Subset-Specific Oscillations in Pro-migratory Factors {#sec2.3}
---------------------------------------------------------------

Given that we had additionally identified rhythmicity in leukocytes to govern the emigration process ([Figure 1](#fig1){ref-type="fig"}C), we next screened blood leukocyte subsets for an oscillatory expression of adhesion molecules and chemokine receptors. Using flow-cytometry analyses across four to six time points of the day, we observed oscillations in adhesion molecules and chemokine receptors, which varied between subsets. Together, they provided a unique rhythmic molecular signature for each lineage ([Figure 3](#fig3){ref-type="fig"}A, [Figures S3](#mmc1){ref-type="supplementary-material"}A--S3C, and [Table S2](#mmc3){ref-type="supplementary-material"}). Focusing on the molecules that exhibited the broadest expression and most robust oscillation patterns, we performed functional blocking experiments by using antibodies or functional inhibitors. Numbers of adoptively transferred leukocytes increased in blood most prominently after injection of antibodies directed against CD49d (α4-integrin) or L-selectin ([Figure 3](#fig3){ref-type="fig"}B). In contrast, no effect was observed when PSGL-1 or the single β1- or β2-integrin subunits were blocked ([Figure 3](#fig3){ref-type="fig"}B and data not shown). Analogous to targeting endothelial cell adhesion molecules, we again observed a stronger effect when antibodies were administered in the evening than when they were administered in the morning ([Figure 3](#fig3){ref-type="fig"}B). We next assessed the functional relevance of oscillatory expression of chemokine receptors on the surface of leukocyte subtypes. Pre-treatment of morning or evening cells with pertussis toxin before adoptive transfer blocked leukocyte homing and ablated its rhythmicity, indicating leukocyte chemokine receptors to be critically involved in this process (data not shown). Specifically, strong effects on numbers and oscillations of adoptively transferred and endogenous leukocyte populations were observed when AMD3100, an antagonist against CXCR4, was administered ([Figures 3](#fig3){ref-type="fig"}C--3E and [Figure S3](#mmc1){ref-type="supplementary-material"}D). In this scenario, leukocyte oscillations ceased in all assessed subtypes, which was also observed when cells were pre-treated with the antagonist *ex vivo* before adoptive transfer ([Figure S3](#mmc1){ref-type="supplementary-material"}E), with the exception of inflammatory monocytes ([Figure 3](#fig3){ref-type="fig"}C). In contrast, blocking other chemokine receptors, including CXCR2 and CCR4 as well as CXCR3, CCR2, and CCR1, did not yield major effects ([Figure 3](#fig3){ref-type="fig"}C and data not shown). These data demonstrate the critical requirement of leukocyte adhesion molecules and CXCR4 in the rhythmic leukocyte migration process. In line with these findings, we observed an oscillation of *Cxcl12* mRNA expression and the CXCR4 ligand in both bone marrow and the lung ([Figure S3](#mmc1){ref-type="supplementary-material"}F). Of importance, this process could be blocked pharmacologically in a time-of-day-dependent manner through the targeting of pro-migratory factors on endothelial cells or leukocytes ([Figure 3](#fig3){ref-type="fig"}F and [Figure S3](#mmc1){ref-type="supplementary-material"}G).Figure 3Leukocyte-Subset-Specific Oscillations in Pro-migratory Molecules(A) Map of rhythmic protein expression of adhesion molecules and chemokine receptors in blood leukocyte subsets (n = 3--6 mice with 4--6 time points measured each; one-way ANOVA).(B) Adoptive transfer of ZT1 and ZT13 donor cells to recipients treated with functional blocking antibodies directed against the indicated molecules at ZT1 and ZT13. Cell numbers are normalized to ZT1 and ZT13 controls (n = 3--12 mice; one-way ANOVA followed by Dunnett comparison to control groups and unpaired Student's t test for comparisons between ZT1 and ZT13 groups).(C) Adoptive transfer of donor cells to recipients treated with antagonists against the indicated molecules at ZT1 and ZT13 (n = 3--10 mice; one-way ANOVA followed by Dunnett comparison to control groups and unpaired Student's t test for comparisons between ZT1 and ZT13 groups).(D) Fold change of donor cells remaining in recipient blood at ZT1 and ZT13 after anti-VCAM-1 and anti-ICAM-1 antibody treatment, respectively, in comparison with numbers of isotype antibody controls. (n = 3 or 4 mice; one-way ANOVA followed by Dunnett comparison to control groups and unpaired Student's t test for comparisons between ZT1 and ZT13 groups).(E) Endogenous blood leukocyte numbers after CXCR4 antagonist treatment (n = 3 or 4 mice; one-way ANOVA followed by Dunnett comparison to control groups and unpaired Student's t test for comparisons between ZT1 and ZT13 groups).(F) Overview of functional blocking effects on adoptively transferred leukocyte subsets in blood targeting the indicated molecules at ZT1 and ZT13 (n = 3--12 mice; one-way ANOVA followed by Dunnett comparison to control groups).^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001; ^\#,\ \#\#,\ \#\#\#,\ \#\#\#\#^ indicate significance levels analogous to those of control groups. All data are represented as mean ± SEM. ns, not significant. See also [Figure S3](#mmc1){ref-type="supplementary-material"} and [Table S2](#mmc3){ref-type="supplementary-material"}.

Diurnal Homing Capacity of Leukocyte Subsets to Specific Organs {#sec2.4}
---------------------------------------------------------------

We next investigated to which organs leukocyte subsets homed over the course of the day. Adoptive transfer of morning or evening cells into phase-matched morning or evening recipients, respectively, demonstrated more leukocyte trafficking to organs in the evening, in line with our data obtained from blood ([Figure 4](#fig4){ref-type="fig"}A and [Figure S4](#mmc1){ref-type="supplementary-material"}A). This excluded excessive phagocytosis or death of leukocytes at specific times as a major contributor to the diurnal effects seen in blood in the employed short time frame of 1 hr. We confirmed this by performing reciprocal homing assays where we co-injected morning or evening cells into morning or evening recipients, respectively, by using differential color labeling ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Specifically, we observed more homing to bone marrow, lymph node, spleen, liver, and lung ([Figure 4](#fig4){ref-type="fig"}A and [Figure S4](#mmc1){ref-type="supplementary-material"}A). We observed very little homing to other investigated tissues, such as skin, thymus, and gut, in the investigated time frame of 1 hr (data not shown). Each leukocyte subset exhibited a unique capacity with respect to rhythmic homing to tissues. More CD4 and CD8 T cells, B cells, and neutrophils migrated to the lymph node in the evening than in the morning ([Figure S4](#mmc1){ref-type="supplementary-material"}A). To the liver, enhanced homing of inflammatory monocytes, neutrophils, B cells, and eosinophils was observed ([Figure 4](#fig4){ref-type="fig"}A). To the lung, more homing of neutrophils, inflammatory monocytes, B cells, eosinophils, and CD8 T cells was observed ([Figure 4](#fig4){ref-type="fig"}A). To the bone marrow, more homing of neutrophils, B cells, inflammatory monocytes, and NK cells was seen, ([Figure S4](#mmc1){ref-type="supplementary-material"}A) and to the spleen, more homing of neutrophils, B cells, and NK cells was detected ([Figure 4](#fig4){ref-type="fig"}A).Figure 4Diurnal Homing Capacity of Leukocyte Subsets to Specific Organs(A) Recruitment of 10^6^ adoptively transferred leukocyte subsets into liver, lung, and spleen at ZT1 and ZT13 (liver, n = 10 mice; lung, n = 10 mice; spleen, n = 24--25 mice; unpaired Student's t test).(B) Recruitment and localization (extravascular or adherent) of 2 × 10^6^ adoptively transferred leukocyte subsets into liver, lung, and spleen at ZT1 and ZT13 (n = 6--12 mice; unpaired Student's t test).(C) Whole-mount imaging of organs defines the location of donor cells in adoptive-transfer experiments after perfusion. Boxes indicate exemplary cells whose localization within tissues is additionally shown in the z direction. Line graphs of mean fluorescence intensities (MFI) show their localization inside or outside the vasculature. Scale bars: 150 μm (overviews for liver, bone marrow \[BM\], lung, and spleen\], 200 μm (for lymph node \[LN\]), 50 μm (low magnification), and 10 μm (high magnification).(D) Quantification of numbers and localization of total transferred cells is based on whole-mount imaging of organs (n = 3 mice; unpaired Student's t test).^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. All data are represented as mean ± SEM. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Because homed cells could have either traversed the endothelium or remained adherent in the vasculature of the respective organ (which would both remove them from the circulation), we additionally assessed the specific location of transferred cells within tissues. To achieve this, we co-injected an anti-CD45 antibody just before perfusion and tissue harvest. This allowed us to distinguish between i.v.-CD45-labeled leukocytes (adherent cells) and non-labeled leukocytes (extravasated cells). In the liver and lung, the vast majority of transferred cells were present in the vasculature ([Figure 4](#fig4){ref-type="fig"}B). In contrast, leukocytes in bone marrow, lymph node, and spleen had predominantly traversed the endothelium ([Figure 4](#fig4){ref-type="fig"}B and [Figure S4](#mmc1){ref-type="supplementary-material"}C). We confirmed these data by performing imaging analyses of organ whole mounts to visualize the precise location of cells in three dimensions ([Figures 4](#fig4){ref-type="fig"}C and 4D). This approach allowed us to additionally assess their locations with respect to organ-intrinsic structures, demonstrating that in the spleen more transferred cells were present in the red pulp than in the white pulp and that cells were extravascular in both areas ([Figure 4](#fig4){ref-type="fig"}C and [Figure S4](#mmc1){ref-type="supplementary-material"}D). Together, these data clearly demonstrate a leukocyte-subset-specific capacity in the rhythmic migration to distinct organs.

Chronopharmacological Targeting of Leukocyte Homing to Tissues {#sec2.5}
--------------------------------------------------------------

We next used the identified targets among pro-migratory factors to assess which leukocyte subset was dependent on which molecule to migrate to which tissue. We built on our previous observations on the time-dependent inhibition of leukocyte emigration from blood ([Figure 3](#fig3){ref-type="fig"}F). We therefore performed the experiments in the evening (ZT13) to maximize the outcome of potential blocking effects and thus detect an influence of molecules that might not have been previously implicated in mediating the migration of leukocyte subsets to specific organs ([Figures 5](#fig5){ref-type="fig"}A--5I).Figure 5Chronopharmacological Targeting of Leukocyte Homing to Tissues(A--H) Adoptive transfer of donor cells to the bone marrow (A and B), lymph node (C and D), spleen (E and F), liver (G), and lung (H) of recipients treated with functional blocking antibodies or antagonists directed against the indicated molecules at ZT13. Cell numbers are normalized to control numbers (n = 4--8 mice; one-way ANOVA followed by Dunnett comparison to the control group). Localization of transferred cells in the bone marrow (B), lymph node (D), and spleen (F) is normalized to control localization (n = 4--8 mice; one-way ANOVA followed by Dunnett comparison to the control group).(I) Images and quantification of localization of donor cells in bone marrow after CXCR4 blockade. Boxes indicate exemplary cells whose localization within tissues is additionally shown in the z direction (n = 3 mice; unpaired Student's t test). Scale bars: 10 μm.(J) Overview of functional blocking effects on leukocyte recruitment to organs, targeting the indicated molecules (n = 4--8 mice; one-way ANOVA followed by Dunnett comparison to the control group).^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001. All data are represented as mean ± SEM. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

As expected for the bone marrow, anti-CXCR4 treatment had the overall strongest blocking effect on all investigated subtypes, with the exception of inflammatory monocytes ([Figure 5](#fig5){ref-type="fig"}A). Specifically, this treatment decreased numbers of extravasated cells but increased numbers of adherent leukocytes inside the vasculature, indicating a specific role in the extravasation process in this tissue ([Figures 5](#fig5){ref-type="fig"}B and 5I and [Figure S5](#mmc1){ref-type="supplementary-material"}A). VCAM-1 inhibition, on the other hand, showed effects in the extravasation of CD4 and CD8 T cells and both the adhesion and extravasation of B cells given that for the latter, both extravascular and intravascular cell numbers were reduced ([Figure 5](#fig5){ref-type="fig"}A and [Figure S5](#mmc1){ref-type="supplementary-material"}A). Blocking ICAM-1 reduced numbers of extravasated B cells, neutrophils, and CD8 T cells ([Figure 5](#fig5){ref-type="fig"}A).

In the lymph node, we observed the most dramatic effect with an antibody directed against L-selectin, which reduced the numbers of all investigated subsets at the step of adhesion and extravasation ([Figures 5](#fig5){ref-type="fig"}C and 5D and [Figure S5](#mmc1){ref-type="supplementary-material"}B). CD11a and ICAM-1 blockade exhibited a similar, albeit slightly weaker effect, indicating their potential co-dependence in this tissue ([Figures 5](#fig5){ref-type="fig"}C and 5D and [Figure S5](#mmc1){ref-type="supplementary-material"}B).

In the spleen, blockade of L-selectin exhibited the strongest effect, particularly on CD8 T cells with additional effects on B cells, neutrophils, and CD4 T cells ([Figures 5](#fig5){ref-type="fig"}E and 5F). Blocking CD11a exhibited specific effects on the ability of B cells to transmigrate given that the number of extravasated cells was reduced and the number of adherent cells was increased ([Figures 5](#fig5){ref-type="fig"}C and 5D and [Figure S5](#mmc1){ref-type="supplementary-material"}C). Anti-ICAM-1 treatment inhibited B cell and inflammatory monocyte immigration ([Figure 5](#fig5){ref-type="fig"}E).

In the liver, numbers of adherent cells could be strongly reduced by interference with VCAM-1 (neutrophils, CD4 T cells, and inflammatory monocytes \[IMs\]), ICAM-1 (B cells, CD4 and CD8 T cells, and IMs), CXCR4 (CD4 T cells and IMs), or CD49d (IMs) ([Figure 5](#fig5){ref-type="fig"}G).

In the lung, numbers of adherent leukocytes could be reduced by blockade of VCAM-1 or ICAM-1 (all subsets except neutrophils), CXCR4, CD49d, or CD11a (B cells, CD4 T cells, and IMs) ([Figure 5](#fig5){ref-type="fig"}H).

Together, these data demonstrate that pro-migratory factors on endothelial cells and leukocytes govern time-of-day-dependent migration, thereby identifying a circadian signature that determines leukocyte migration to tissues ([Figure 5](#fig5){ref-type="fig"}J and [Figure S5](#mmc1){ref-type="supplementary-material"}D).

Lineage-Specific Clock Deficiency Ablates Migration Rhythms {#sec2.6}
-----------------------------------------------------------

We next investigated the relevance of a functional clock in the rhythmic trafficking behavior of immune cells. We first focused on the microenvironment by using *Cdh5*^*CreERT2*^*Bmal1*^*flox/flox*^ mice to specifically delete the circadian gene brain and muscle Arnt-like protein-1 (*Bmal1*, also known as *Arntl*) in endothelial cells ([@bib44]). *Bmal1* is a core component of the cellular clockwork and the only single gene whose deficiency causes an ablation of circadian rhythmicity ([@bib39]). Using these mice as recipients, we performed homing experiments and quantified the amount of adoptively transferred cells that remained in the blood. Interestingly, whereas control mice showed fewer transferred cells in the circulation in the evening, mice with *Bmal1*-deficient endothelial cells showed no difference between time points for all subsets examined ([Figure 6](#fig6){ref-type="fig"}A). We next investigated whether rhythmic homing to tissues was also ablated. Indeed, in the two organs displaying the strongest oscillations, the lung and liver, time-of-day differences were lost ([Figure 6](#fig6){ref-type="fig"}B). These observations were associated with strongly reduced evening expression of ICAM-1 and VCAM-1 in the liver and lung, respectively, of mice with *Bmal1*^−/−^ endothelial cells ([Figure 6](#fig6){ref-type="fig"}C). This genetically demonstrates the relevance of oscillations in the microenvironment and indicates that within tissues, the endothelial-cell-specific clock plays a critical role in governing rhythmic leukocyte recruitment.Figure 6Lineage-Specific Clock Deficiency Ablates Migration Rhythms(A) Numbers of adoptively transferred donor cells present in the blood of control recipients or recipients with *Bmal1*-deficient endothelial cells 1 hr after transfer at ZT1 and ZT13 (n = 3 or 4 mice; unpaired Student's t test).(B) Adoptive transfer of donor cells to the liver and lung of control recipients or recipients with *Bmal1*-deficient endothelial cells 1 hr after transfer at ZT1 and ZT13 (n = 5 mice; unpaired Student's t test).(C) Expression of endothelial cell ICAM-1 and VCAM-1 in liver and lung of control mice and mice with *Bmal1*-deficient endothelial cells at ZT1 and ZT13 (n = 4--7 mice; one-way ANOVA).(D) Adoptive transfer of control or *Bmal1*-deficient B cells to the spleen and lymph node of wild-type recipients 1 hr after transfer at ZT1 and ZT13 (n = 6 mice; unpaired Student's t test).(E) qPCR analysis of *N1rd1* mRNA expression in isolated control and *Bmal1*-deficient B cells (n = 3 mice; one-way ANOVA).(F) CD11a and CD49d expression on control and *Bmal1*-deficient B cells in blood at ZT13 (n = 8 mice; unpaired Student's t test).(G) Adoptive transfer of control or *Bmal1*-deficient neutrophils to the spleen of wild-type recipients 1 hr after transfer at ZT1 and ZT13 (n = 6 mice; unpaired Student's t test).(H) qPCR analyses of *N1rd1* mRNA expression in isolated control and *Bmal1*-deficient neutrophils (n = 3 mice; one-way ANOVA).(I) PSGL-1 expression on control and *Bmal1*-deficient neutrophils in blood at ZT13 (n = 4 or 5 mice; unpaired Student's t test).^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. All data are represented as mean ± SEM. ns, not significant. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

To assess the influence of clocks in leukocytes in this phenomenon, we used *Cd19*^*Cre*^*Bmal1*^*flox/flox*^ mice as donors to evaluate the homing capacity of clock-deficient B cells. Transferred *Bmal1*^−/−^ B cells exhibited no more time-dependent homing to the spleen or lymph nodes of wild-type recipients ([Figure 6](#fig6){ref-type="fig"}D). In addition, *Bmal1*^−/−^ B cells displayed diminished oscillations in the clock gene *Nr1d1* (Rev-Erbα) ([Figure 6](#fig6){ref-type="fig"}E) and reduced surface amounts of CD11a and CD49d ([Figure 6](#fig6){ref-type="fig"}F), as well as CCR7 and CXCR5 (but not CXCR4 or L-selectin) ([Figure S6](#mmc1){ref-type="supplementary-material"}A and data not shown). Using *Lyz2*^*Cre*^*Bmal1*^*flox/flox*^ mice to target the clock in myeloid cells, we also observed a lack of oscillations in the migration behavior of donor neutrophils to the spleen of wild-type recipients ([Figure 6](#fig6){ref-type="fig"}G). *Bmal1*^−/−^ neutrophils ([Figure 6](#fig6){ref-type="fig"}H) and monocytes ([Figure S6](#mmc1){ref-type="supplementary-material"}B) displayed altered *Nr1d1* expression. Neutrophils exhibited lower expression of PSGL-1 ([Figure 6](#fig6){ref-type="fig"}I), whereas monocytes showed altered amounts of L-selectin (*Sell*), CCR2, and CD18 integrin ([Figures S6](#mmc1){ref-type="supplementary-material"}B and S6C). Together, these data genetically demonstrate that both endothelial cell and leukocyte clocks are critically required for a rhythmic homing process by regulating the expression of pro-migratory factors.

Relevance of Rhythmic Leukocyte Trafficking in Inflammation and Leukemia {#sec2.7}
------------------------------------------------------------------------

We next explored the relevance of oscillatory leukocyte trafficking for the immune response by using a systemic inflammatory challenge with intraperitoneally injected lipopolysaccharide (LPS). After acute stimulation, leukocyte counts in blood exhibited a dramatic drop, but time-of-day differences of leukocyte subsets, which exhibited lower numbers in the evening for all investigated subsets, were preserved ([Figure 7](#fig7){ref-type="fig"}A). This indicates the importance of rhythmic leukocyte migration for the strength of the immune response given that, indeed, tissue infiltration into the peritoneal cavity was rhythmic ([Figure S7](#mmc1){ref-type="supplementary-material"}A). In addition, the administration of antibodies directed against VCAM-1, ICAM-1, or CD49d was able to block this effect in a subset-specific manner, whereas anti-CD11a treatment exhibited no effect. Even after the use of inflammatory challenge, antibodies exerted a stronger inhibitory effect on leukocyte emigration from blood at night ([Figures 7](#fig7){ref-type="fig"}A and 7B). Together, these data indicate the relevance of oscillatory leukocyte migration in determining the strength of the immune response.Figure 7Relevance of Rhythmic Leukocyte Trafficking in Inflammation, Leukemia, and Humans(A) Blood leukocyte numbers after acute treatment without (ctrl) or with LPS in combination with functional blocking antibodies directed against the indicated molecules at ZT1 and ZT13 (n = 3--12 mice; one-way ANOVA followed by Dunnett comparison to the LPS group and unpaired Student's t test for comparisons between ZT1 and ZT13 groups).(B) Overview of functional blocking effects on leukocyte subsets in blood after LPS treatment targeting the indicated molecules at ZT1 and ZT13 (n = 3--12 mice; one-way ANOVA).(C) Numbers of circulating blasts present in the blood of C57BL/6J CD45.1 recipients at midday 1 week after engraftment at ZT1 and ZT13 with mouse C1498 (AML) or BS50 (B-ALL) cells (n = 7 or 8 mice; Mann-Whitney test).(D) Numbers of circulating blasts present in the blood of NSG recipient mice at midday 1 week after engraftment at ZT1 and ZT13 with human NALM-6 B-ALL cells (n = 8 mice; unpaired Student's t test).(E) Oscillation of blood B cell numbers in human blood (n = 8 subjects; repeated-measures one-way ANOVA).(F) CXCR4 expression on human B cells over 24 hr (n = 8 subjects; repeated-measures one-way ANOVA).(G) Transendothelial migration (TEM) capacity of human primary B cells harvested from three donors at 11 a.m. and 7 p.m. across HUVECs. Numbers are normalized to 11 a.m. levels (n = 4 assays; unpaired Student's t test).(H and I) Blocking efficacy of AMD3100 (H) or an anti-LFA-1 antibody (I) on TEM capacity of human primary B cells harvested at 11 a.m. and 7 p.m. Numbers are normalized to and compared with those of vehicle and isotype controls, respectively (n = 3 donors; unpaired Student's t test).(J and K) Example of the TEM capacity of human B cells from one patient at 11 a.m. and 7 p.m. after AMD3100 (J) or anti-LFA-1 treatment (K) plotted over time (n = 4 assays; two-way ANOVA with Tukey post-test).^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001; ^\#,\ \#\#,\ \#\#\#,\ \#\#\#\#^ indicate significance levels analogous to those of the LPS groups. All data are represented as mean ± SEM. ns, not significant. See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

We additionally explored a disease model by using a leukemia cancer model where tumor burden is measured in blood. We used both a syngeneic and a xenogeneic model of acute myeloid leukemia (AML) and B cell acute lymphoblastic leukemia (B-ALL). In the syngeneic model, CD45.1^+^ wild-type mice were injected i.v. with 5 × 10^6^ CD45.2^+^ C1498 (AML) or BS50 (B-ALL) cells either in the morning (ZT1) or in the evening (ZT13). After 1 week, we measured numbers of circulating AML or B-ALL blasts at midday on the basis of CD45.2 expression to allow the assessment of the influence of the time of day of administration only and not the harvest. Interestingly, the rate of engraftment, defined as more than one blast per microliter, was much higher in the evening for both models (5/16 in the morning versus 13/16 in the evening), and circulating blasts were significantly higher at night than in the morning ([Figure 7](#fig7){ref-type="fig"}C). This indicates that homing and engraftment of leukemic cells is strongly time-of-day dependent. Because rhythms in the host immune response might influence tumor burden in a time-of-day-dependent manner, we additionally employed a xenogeneic model by using immune-deficient non-obese diabetic (NOD) scid *Il2rg*^−/−^ (NSG) mice, which have no functional adaptive immune system and lack functional NK cells. We injected 5 × 10^6^ NALM-6 cells, a human B-ALL cell line, either in the morning or in the evening. After 1 week, numbers of circulating human blasts at midday were significantly higher when cells had been injected at night ([Figure 7](#fig7){ref-type="fig"}D), confirming that time-of-day-dependent recruitment and engraftment are highly relevant for tumor burden.

Rhythms in Human Leukocyte Migration {#sec2.8}
------------------------------------

We finally investigated the presence of oscillations in leukocyte trafficking for humans. Using flow cytometry of human blood harvested over five time points of the day, we found that total WBC was oscillatory but had an inverted pattern compared with the one observed in mice, namely higher numbers in the evening (7 p.m.) and a trough in the morning ([Figures S7](#mmc1){ref-type="supplementary-material"}B--S7C), in line with previous observations ([@bib4]). Within leukocyte subsets, we observed the strongest oscillations in B cells ([Figure 7](#fig7){ref-type="fig"}E) as well as CD4 and CD8 T cells ([Figure S7](#mmc1){ref-type="supplementary-material"}C), and other populations showed a similar trend ([Figure S7](#mmc1){ref-type="supplementary-material"}C). Similar to murine cell numbers, neutrophil numbers peaked during the day ([Figure S7](#mmc1){ref-type="supplementary-material"}C). With the exception of neutrophils, higher amounts of subsets in blood were inversely correlated with CXCR4 amounts ([Figure 7](#fig7){ref-type="fig"}F and [Figure S7](#mmc1){ref-type="supplementary-material"}D), indicating that molecules we found to be of key importance in mice were also most likely responsible for driving rhythmic leukocyte migration processes in humans. We therefore assessed the rhythmic migratory capacity of human primary B cells ([@bib5]) because these showed the strongest oscillations among subsets. Interestingly, blood B cells harvested in the morning exhibited a significantly higher rate of transmigration across human umbilical vein endothelial cells (HUVECs) than cells harvested from the same donors at night ([Figure 7](#fig7){ref-type="fig"}G). Strikingly, this process could be blocked efficiently in the morning by the CXCR4 antagonist AMD3100 or an antibody directed against LFA-1, whereas no significant effect was observed at night ([Figures 7](#fig7){ref-type="fig"}H--7K). Thus, these data demonstrate that human leukocytes have a rhythmic homing capacity that peaks at inverse times compared with those in mice but uses analogous molecules in the process. Altogether, we describe here a circadian signature that guides rhythmic leukocyte homing in mice and humans in steady-state, inflammation, and disease conditions.

Discussion {#sec3}
==========

Here, we have shown a broad and rhythmic program that governs the migration patterns of leukocyte subsets throughout the body over the course of the day. We have determined an organ- and leukocyte-subset-specific functional rhythmic signature of pro-migratory factors on endothelial cells and leukocytes. Rhythmicity in both the endothelium and leukocyte contributes to this process given that a genetically induced lack of a functional clock in either ablates time-of-day differences. We have thus identified an extensive, time-of-day-dependent trafficking zip code that guides migration of leukocytes to organs.

The process of leukocyte migration to tissues has long been studied, and multiple molecules have been implicated ([@bib20], [@bib27], [@bib42], [@bib43]). Yet, no broad systematic approach has been undertaken for investigating the effects of multiple molecules, leukocyte subsets, and organs, particularly under non-inflammatory, steady-state conditions and with respect to the time of day. We incorporated the element of time to identify potential phases of the day when leukocyte migration to tissues and its blockade would show maximal effects. We determined this time to be the evening, or more precisely 1 hr after lights off, when mice are at the beginning of the behavioral activity phase.

The broad expression profile of VCAM-1 across all organs and its functional implications for the migration of many leukocyte subsets in steady-state conditions were unexpected given that previous studies had generally associated the molecule with inflammatory scenarios ([@bib36]). Indeed, our data indicate that during the day, when most other studies were probably performed, VCAM-1 is hardly expressed and plays no functional role. However, expression of VCAM-1 increases over the day and exhibits a function in the evening. Thus, our approach allowed us to identify roles for molecules that had previously not been implicated in the migration of specific leukocyte subsets to organs.

For each organ and leukocyte subset, we detected a very distinct molecular homing signature. Blood leukocyte counts and bone marrow recruitment were strongly governed by CXCR4, which affected the migration of all investigated leukocyte subsets, with the exception of inflammatory monocytes. In other organs, the dependency on CXCR4 was reduced and much more subset specific. In addition to the known effect of VCAM-1 and VLA-4 in bone marrow homing, targeting ICAM-1 exhibited a broad inhibitory effect on many investigated subsets, with the exception of CD4 T cells and IMs. In addition, we also detected a role for L-selectin in neutrophil homing to this tissue. To our knowledge, ICAM-1 and L-selectin have previously not been associated with bone marrow homing given that the classical homing receptors on the endothelium consist of VCAM-1, E-selectin, and P-selectin ([@bib25]).

In the lymph node, an almost complete lack of homing was observed for all leukocyte subsets when L-selectin was blocked, in agreement with previous reports ([@bib1], [@bib13]). L-selectin was also the dominant molecule regulating leukocyte migration to the spleen, particularly for CD8 T cells, which is an unexpected finding given that previous reports have not implicated a role for this molecule in this organ ([@bib29]). Also, in the lymph node we found a significant number of neutrophils and inflammatory monocytes, subsets that have generally not been investigated in this tissue under steady-state conditions ([@bib14], [@bib15]). Trafficking of neutrophils to the lymph node was dependent on L-selectin, CD11a, CXCR4, ICAM-1, and CD49d, whereas IMs relied mostly on L-selectin. The presence of small but detectable populations in this tissue expands the known trafficking routes of these subsets, particularly of the short-lived neutrophils. The functional relevance of their presence in steady-state conditions in lymph nodes for immune functions remains to be elucidated.

Although to our knowledge details on molecules mediating adhesion in the liver and lung under steady-state conditions are currently lacking for neutrophils and monocytes ([@bib10], [@bib19], [@bib21], [@bib26], [@bib31]), we found a small role for VCAM-1 in neutrophil recruitment in the liver. This finding is of physiological relevance because it is the likely explanation for the observed higher numbers of transferred neutrophils in blood when VCAM-1 is blocked. VCAM-1, ICAM-1, VLA-4, and CXCR4 strongly regulated homing of monocytes to the liver, a finding very similar to that in the lung, where additional effects on LFA-1 were observed. Although the functional importance for VLA-4, VCAM-1, and ICAM-1 has been shown for CD8 T cells in the liver before ([@bib3], [@bib16]), we have now extended these observations to inflammatory monocytes. An interesting effect that we observed was that targeting VLA-4 increased numbers of B cells in this tissue. Also, blockade of L-selectin increased neutrophil adhesion. This indicates that in a scenario of leukocytosis induced by targeting VLA-4 (most likely due to effects in the bone marrow), B cells accumulate in the liver in an unspecific manner. In contrast, whereas blocking VCAM-1 showed a similar reduction on B cell homing to the bone marrow, more B cells accumulated in the spleen in this scenario. This demonstrates the distribution dynamics and the highly tissue- and subset-specific nature of the leukocyte homing process.

The high number of organs, leukocyte subsets, and molecules investigated prevented us from performing functional migration analyses for tissues where little homing occurred. In addition, combining the effects of multiple antibodies or antagonists to assess overlapping functions was outside the scope of this study. Our initial screening procedure in blood allowed us to detect the more dramatic, organism-wide effects, whereas smaller, tissue-specific effects might not have been detectable in some cases. We additionally focused here on events occurring at the blood-tissue interphase as the gate-keeping mechanism for leukocyte infiltration to tissues and thus did not investigate broad chemokine profiles of organs (with the exception of *Cxcl12*), something that would be strongly dependent on other tissue-resident cells, such as fibroblasts ([@bib30]). Another important factor that we did not investigate is the heterogeneity of leukocyte subpopulations in blood. Neutrophils are probably the most heterogeneous population with respect to their age as a result of their relatively short lifespan compared with that of other subsets. Thus, most neutrophils present in blood in the morning are probably just mobilized from the bone marrow and thus represent young cells, whereas in the evening this subset has already aged significantly ([@bib7], [@bib45]). In contrast, most lymphocytes are a mixture of cells released from the thymus or bone marrow and cells that have reached the blood from the lymph and thus have spent a significant amount of time before in tissues. Our markers did not allow for further specification within individual leukocyte subsets. Therefore, which subsets are more prominently affected by our pharmacological interventions could not be addressed. At least for T lymphocytes, however, we have previously observed that naive, effector memory and central memory cells behave very similarly with respect to their oscillations in the blood ([@bib11]). These questions should be addressed in follow-up studies focusing on specific tissues and leukocyte subsets.

We found that time of day for antibody and antagonist administration had a great impact on their efficacy in steady-state conditions and after inflammatory challenge. In fact, for VCAM-1 and L-selectin, as well as for some subsets for CD49d, CXCR4, and ICAM-1, we hardly observed any effect in the morning. This provides a potential window for therapy with respect to targeting leukocyte trafficking at specific times. Current clinical therapeutic approaches targeting leukocyte surface molecules include natalizumab (Tysabri), a neutralizing antibody that acts against the α~4~ subunit of VLA-4 and is used in the treatment of multiple sclerosis ([@bib17]). This drug is currently given at one time point of the day, but future studies should investigate the effect of timing drug administration in this scenario. Relapses in patients with multiple sclerosis are negatively correlated with the abundance of the night-signaling hormone melatonin in the serum ([@bib12]). This is linked to a seasonal exacerbation of symptoms in the spring ([@bib12]). Multiple sclerosis could additionally have a diurnal component to it given that the experimental autoimmune encephalomyelitis (EAE) animal model of multiple sclerosis shows strong time-of-day dependency in disease severity ([@bib11], [@bib40]).

An important finding of this study is the fact that homing and engraftment capacities of leukemic cancer cells lines, both murine and human, are highly time-of-day dependent, given that administration of cells in the evening dramatically increased tumor burden a week later. This was not dependent on potential rhythmic immunogenicity of the graft because similar effects were observed in immune-deficient and immune-competent animals. Thus, time of day is an important factor for leukemia burden in mouse and human models of this disease.

These observations are of particular relevance given that we showed that rhythms in leukocyte homing extend to humans, where an inverse rhythmicity in blood leukocyte counts, particularly for lymphocyte populations, was observed. The variability between subjects was surprisingly small, given that the genetic differences between individuals are vastly greater than those between inbred mice used and that feeding and lighting schedules had not been synchronized. The strongly time-of-day-dependent transmigration capacity of human B cells could be blocked by the targeting of CXCR4, which we demonstrate to be rhythmically expressed on this subset, as well as that of LFA-1. This indicates the benefit of a chronotherapeutic approach for targeting either protein in the clinic. Indeed, targeting the CXCR4-CXCL12 axis with G-CSF has already been demonstrated to more strongly mobilize hematopoietic stem and progenitor cells in the afternoon ([@bib22]).

The inverse rhythmicity of human oscillations has thus far been linked to the altered behavioral rhythms of mice and humans such that it yields higher levels during the behavioral rest phase in both nocturnal (mice) and diurnal (humans) species. Recent data, however, demonstrate that rhythmicity in blood leukocyte counts can be decoupled from behavior and relies on reactive oxygen species in a manner independent of the microenvironment ([@bib46]). Our data demonstrate that both endothelial cells and leukocytes themselves co-govern rhythmic leukocyte migration but that lack of a clock in either is sufficient in disturbing it. The observations that a high number of pro-migratory factors display diurnal oscillations point to a role of the circadian clock in their regulation. Many of these factors exhibit binding sites for transcription factors BMAL1 and CLOCK in their promoter regions, which warrants further systematic investigations into the direct clock control of these molecules. Interplay between cell-intrinsic and -extrinsic signals appears to regulate total blood cellularity, most likely by modulating both the mobilization of cells into the circulation and the emigration, the latter of which was the subject of the present study.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-mouse CD3, PE/DZL594, clone 17A2BiolegendCat\# 100246, RRID: [AB_2565883](nif-antibody:AB_2565883){#intref0010}Anti-mouse CD3ε, Alexa Fluor® 488, clone 145-2C11BiolegendCat\# 100321, RRID: [AB_389300](nif-antibody:AB_389300){#intref0015}Anti-mouse CD4, Brilliant Violet 570, clone RM4-5BiolegendCat\# 100542, RRID: [AB_2563051](nif-antibody:AB_2563051){#intref0020}Anti-mouse CD4, PE, clone GK1.5BiolegendCat\# 100408, RRID: [AB_312693](nif-antibody:AB_312693){#intref0025}Anti-mouse CD4, APC, clone GK1.5BiolegendCat\# 100412, RRID: [AB_312697](nif-antibody:AB_312697){#intref0030}Anti-mouse CD4, APC/Cy7, clone GK1.5BiolegendCat\# 100714, RRID: [AB_312753](nif-antibody:AB_312753){#intref0035}Anti-mouse CD8a, PE/Cy7, clone 53-6.7BiolegendCat\# 100722, RRID: [AB_100722](nif-antibody:AB_100722){#intref0040}Anti-mouse CD8a, APC/Cy7, clone 53-6.7BiolegendCat\# 100714, RRID: [AB_312753](nif-antibody:AB_312753){#intref0045}Anti-mouse CD8a, PE-CF594, clone 53-6.7BD BioscienceCat\# 562283Anti-mouse CD8a, Alexa Fluor® 700, clone 53-6.7BiolegendCat\# 100730, RRID: [AB_493703](nif-antibody:AB_493703){#intref0050}Anti-mouse/human CD11b, Alexa Fluor® 700, clone M1/70BiolegendCat\# 101222, RRID: [AB_493705](nif-antibody:AB_493705){#intref0055}Anti-mouse CD115, PE, clone AFS98BiolegendCat\# 135506, RRID: [AB_1937253](nif-antibody:AB_1937253){#intref0060}Anti-mouse CD115, APC, clone AFS98eBioscienceCat\# 135510, RRID: [AB_2085221](nif-antibody:AB_2085221){#intref0065}Anti-mouse Gr-1, PerCP/Cy5.5, clone RB6-8C5BiolegendCat\# 108428, RRID: [AB_893558](nif-antibody:AB_893558){#intref0070}Anti-mouse Gr-1, FITC, clone RB6-8C5BiolegendCat\# 108406, RRID: [AB_313371](nif-antibody:AB_313371){#intref0075}Anti-mouse/human CD45R/B220, Alexa Fluor® 488, clone RA3-6B2BiolegendCat\# 103225, RRID: [AB_389308](nif-antibody:AB_389308){#intref0080}Anti-mouse/human CD45R/B220, PE/Cy7, clone RA3-6B2BiolegendCat\# 103222, RRID: [AB_313005](nif-antibody:AB_313005){#intref0085}Anti-mouse/human CD45R/B220, APC-Cy7, clone RA3-6B2BiolegendCat\# 103224, RRID: [AB_313007](nif-antibody:AB_313007){#intref0090}Anti-mouse Siglec-F, Alexa Fluor® 647, clone E50-2440BD BioscienceCat\# 562680Anti-mouse Siglec-F, APC-Cy7, clone E50-2440BD BioscienceCat\# 565527Anti-mouse NK1.1, APC, clone PK136BiolegendCat\# 108710, RRID: [AB_313397](nif-antibody:AB_313397){#intref0095}Anti-mouse NK1.1, Alexa Fluor® 700, clone PK136ebioscienceCat\# 56-5941-80, RRID: [AB_2574504](nif-antibody:AB_2574504){#intref0100}Anti-mouse NK1.1, PE/Cy7, clone PK136BiolegendCat\# 108714, RRID: [AB_389364](nif-antibody:AB_389364){#intref0105}Anti-mouse NK1.1, PE/Cy5, clone PK136BiolegendCat\# 108716, RRID: [AB_493590](nif-antibody:AB_493590){#intref0110}Anti-mouse CD45, PE/Dazzle 594, clone 30-F11BiolegendCat\# 103146, RRID: [AB_2564003](nif-antibody:AB_2564003){#intref0115}Anti-mouse CD45, PE, clone 30-F11BiolegendCat\# 103106, RRID: [AB_312971](nif-antibody:AB_312971){#intref0120}Anti-mouse CD45, APC, clone I3/2.3BiolegendCat\# 147708, RRID: [AB_2563540](nif-antibody:AB_2563540){#intref0125}Anti-mouse CD45.1, PE-CF594, clone A20BD BiosciencesCat\# 562452Anti-mouse CD45.2, Alexa Fluor® 700, clone 104BiolegendCat\#109822, RRID: [AB_493731](nif-antibody:AB_493731){#intref0130}Anti-mouse CD45, eFluor780, clone 30-F11eBiosciencesCat\# 47-0451-82, RRID: [AB_1548781](nif-antibody:AB_1548781){#intref0135}Anti-mouse Ly6C, PE, clone HK1.4BiolegendCat\# 128008, RRID: [AB_1186132](nif-antibody:AB_1186132){#intref0140}Anti-mouse Ly6G, PerCP/Cy5.5, clone 1A8BiolegendCat\# 127616, RRID: [AB_1877271](nif-antibody:AB_1877271){#intref0145}Anti-mouse I-A/I-E, PE/Cy7, clone M5/114.15.2BiolegendCat\# 107630, RRID: [AB_2069376](nif-antibody:AB_2069376){#intref0150}Anti-mouse CCR1, PE, clone 643854R&DCat\# FAB5986P-100Anti-mouse CCR2, Alexa Fluor® 700, clone 475301R&DCat\# FAB5538N-100Anti-mouse CCR3, FITC, clone J073E5BiolegendCat\# 144510, RRID: [AB_2561609](nif-antibody:AB_2561609){#intref0155}Anti-mouse CCR3, PE, clone J073E5BiolegendCat\# 144506, RRID: [AB_2561534](nif-antibody:AB_2561534){#intref0160}Anti-mouse CCR4, PE/Cy7, clone 2G12BiolegendCat\# 131214, RRID: [AB_2244410](nif-antibody:AB_2244410){#intref0165}Anti-mouse CCR5, PE, clone HM-CCR5BiolegendCat\# 107006, RRID: [AB_313301](nif-antibody:AB_313301){#intref0170}Anti-mouse CCR6, PerCp/Cy5.5, clone 29-2L17BiolegendCat\# 129810, RRID: [AB_2275515](nif-antibody:AB_2275515){#intref0175}Anti-mouse CCR7, PE, clone 4B12BiolegendCat\# 120106, RRID: [AB_389358](nif-antibody:AB_389358){#intref0180}Anti-mouse CCR8, PE, clone 1055cR&DCat\# FAB8324P-100Anti-mouse CCR9, PE, clone 9B1BiolegendCat\# 129708, RRID: [AB_2073249](nif-antibody:AB_2073249){#intref0185}Anti-mouse CCR10, Alexa Fluor® 700, clone 248918R&DCat\# FAB2815N-100Anti-mouse CXCR2, PE, clone 242216R&DCat\# FAB2164P-100Anti-mouse CXCR3, PE/Cy7, clone CXCR3-173BiolegendCat\# 126516, RRID: [AB_2245493](nif-antibody:AB_2245493){#intref0190}Anti-mouse CXCR4, PE, clone L276F12BiolegendCat\# 146506, RRID: [AB_2562783](nif-antibody:AB_2562783){#intref0195}Anti-mouse CXCR4, PerCP/Cy5.5, clone L276F12BiolegendCat\# 146510, RRID: [AB_2562787](nif-antibody:AB_2562787){#intref0200}Anti-mouse CXCR5, PE, clone L138D7BiolegendCat\# 145504, RRID: [AB_2561968](nif-antibody:AB_2561968){#intref0205}Anti-mouse CXCR6, PerCP, clone 221002R&DCat\# FAB2145C-100Anti-mouse CX3CR1, PerCP Cy 5.5, clone SA011F11BiolegendCat\# 149010, RRID: [AB_2564494](nif-antibody:AB_2564494){#intref0210}Anti-mouse CD11a, PerCP/Cy5.5, clone M17/4BiolegendCat\# 101124, RRID: [AB_2562932](nif-antibody:AB_2562932){#intref0215}Anti-mouse/human CD11b, Alexa Fluor® 700, clone M1/70BiolegendCat\# 101222, RRID: [AB_493705](nif-antibody:AB_493705){#intref0220}Anti-mouse CD11c, Alexa Fluor® 700, clone N418BiolegendCat\# 117320, RRID: [AB_528736](nif-antibody:AB_528736){#intref0225}Anti-mouse CD44, PE-CF594, clone IM7BD BioscienceCat\# 562464Anti-mouse CD62L, APC/Cy7, clone MEL-14BiolegendCat\# 104428, RRID: [AB_830799](nif-antibody:AB_830799){#intref0230}Anti-mouse CD162, PE, clone 2PH1BD bioscienceCat\# 555306Anti-mouse CD18, PerCP-Cy5.5, clone C71/16BD BioscienceCat\# 562827Anti-mouse/rat CD29, Alexa Fluor® 700, clone HMβ1-1BiolegendCat\# 102218, RRID: [AB_493711](nif-antibody:AB_493711){#intref0235}Anti-mouse CD49b, PE/Cy7, clone DX5BiolegendCat\# 108922, RRID: [AB_2561460](nif-antibody:AB_2561460){#intref0240}Anti-mouse CD49d, PerCP/Cy5.5, clone R1-2BiolegendCat\# 103620, RRID: [AB_2563702](nif-antibody:AB_2563702){#intref0245}Anti-mouse CD49e, PE-CF594, clone 5H10-27 (MFR5)BD BioscienceCat\# 564313Anti-mouse/human CD49f, PE/Cy7, clone GoH3BiolegendCat\# 313622, RRID: [AB_2561705](nif-antibody:AB_2561705){#intref0250}Anti-human CD8, Alexa Fluor® 488, clone HIT8aBiolegendCat\# 300916, RRID: [AB_756152](nif-antibody:AB_756152){#intref0255}Anti-human CD19, PE, clone HIB19BiolegendCat\# 302208, RRID: [AB_314238](nif-antibody:AB_314238){#intref0260}Anti-human CD56, PE/Dazzle 594, clone HCD56BiolegendCat\# 318348, RRID: [AB_2563564](nif-antibody:AB_2563564){#intref0265}Anti-human CD14, PerCP/Cy5.5, clone HCD14BiolegendCat\# 325622, RRID: [AB_893250](nif-antibody:AB_893250){#intref0270}Anti-human CD16, PE/Cy7, clone 3G8BiolegendCat\# 302016, RRID: [AB_314216](nif-antibody:AB_314216){#intref0275}Anti-human CD49d, APC, clone 9F10BiolegendCat\# 304308, RRID: [AB_2130041](nif-antibody:AB_2130041){#intref0280}Anti-human CD4, Alexa Fluor® 700, clone SK3BiolegendCat\# 344622, RRID: [AB_2563150](nif-antibody:AB_2563150){#intref0285}Anti-human CXCR4, APC/Cy7, clone 12G5BiolegendCat\# 306528, RRID: [AB_2565994](nif-antibody:AB_2565994){#intref0290}Anti-human CD3, Brilliant Violet 570, clone UCHT1BiolegendCat\# 300436, RRID: [AB_2562124](nif-antibody:AB_2562124){#intref0295}Anti-human CD45, PE, clone HI30BD PharMingenCat\# 555483, RRID: [AB_395875](nif-antibody:AB_395875){#intref0300}Anti-mouse Armenian Hamster IgG, Alexa Fluor® 700, clone HTK888BiolegendCat\# 400926Anti-mouse Armenian Hamster IgG, PE, clone HTK888BiolegendCat\# 400908Anti-mouse Armenian Hamster IgG, Pe/Cy7, clone HTK888BiolegendCat\# 400922Anti-mouse Armenian Hamster IgG, PerCp/Cy5.5, clone HTK888BiolegendCat\# 400932Anti-mouse Mouse IgG 1, κ, PE, clone P3.6.2.8.1eBioscienceCat\# 12-4714-41Anti-mouse Rat IgG1, κ, PE, clone R3-34BD bioscienceCat\# 553925Anti-mouse Rat IgG2a, κ, Alexa Fluor® 488, clone RTK2758BiolegendCat\# 400525Anti-mouse Rat IgG2a, κ, Alexa Fluor® 700, clone eBR2aeBioscienceCat\# 56-4321-80Anti-mouse Rat IgG2a, k, APC/Cy7, clone RTK2758BiolegendCat\# 400524Anti-mouse Rat IgG2a, κ, PE, clone RTK2758BiolegendCat\# 400508Anti-mouse Rat IgG2a, κ, PE-CF594, clone R35-95BD BioscienceCat\# 562302Anti-mouse Rat IgG2a, κ, PE/Cy7, clone RTK2758BiolegendCat\# 400522Anti-mouse Rat IgG2a, κ, PerCp/Cy5.5, clone RTK2758BiolegendCat\# 400532Anti-mouse Mouse IgG2a, κ, PerCp/Cy5.5, clone MOPC-173BiolegendCat\# 400258Anti-mouse Rat IgG2b, κ, Alexa Fluor® 700, clone RTK4530BiolegendCat\# 400628Anti-mouse Rat IgG2b, κ, PE, clone RTK4530BiolegendCat\# 400610Anti-mouse Rat IgG2b, κ, PE/Cy7, clone RTK4530BiolegendCat\# 400618Anti-mouse Rat IgG2b, κ, PE CP594, clone A95-1BD BioscienceCat\# 562308Anti-mouse Rat IgG2b, κ, PerCP/Cy5.5, clone RTK4530BiolegendCat\# 400632Anti-mouse ICAM-1, PE, clone YN1/1.7.4BiolegendCat\# 116108, RRID: [AB_313699](nif-antibody:AB_313699){#intref0305}Anti-mouse VCAM-1, PE, clone 429 (MVCAM.A)BiolegendCat\# 105714, RRID: [AB_1134164](nif-antibody:AB_1134164){#intref0310}Anti-mouse E-selectin, PE, clone 10E9.6 (RUO)BD BioscienceCat\# 553751Anti-mouse/human P-selectin, PE, clone Psel.KO2.3eBioscienceCat\# 2-0626-80, RRID: [AB_1210864](nif-antibody:AB_1210864){#intref0315}Anti-mouse MadCAM, Alexa Fluor® 488, clone MECA-367BiolegendCat\# 120708, RRID: [AB_493398](nif-antibody:AB_493398){#intref0320}Anti-mouse ICAM-2, Alexa Fluor® 488, clone 3C4 (MIC2/4)BiolegendCat\# 105609, RRID: [AB_2264501](nif-antibody:AB_2264501){#intref0325}Anti-mouse/human PNAd, Biotin, clone MECA-79BiolegendCat\# 120804, RRID: [AB_493557](nif-antibody:AB_493557){#intref0330}Anti-mouse PECAM-1, Alexa Fluor® 647, clone MEC13.3BiolegendCat\# 102516, RRID: [AB_2161029](nif-antibody:AB_2161029){#intref0335}Anti-mouse PECAM-1, APC, clone 390BiolegendCat\# 102410, RRID: [AB_312905](nif-antibody:AB_312905){#intref0340}Anti-mouse/human CD44, PE, clone IM7BiolegendCat\# 103008, RRID: [AB_312959](nif-antibody:AB_312959){#intref0345}Streptavidin, Cy3BiolegendCat\# 405215Anti-mouse Rat IgM, κ, Biotin, clone RTK2118BiolegendCat\# 400804Anti-mouse Rat IgG2a, κ, PE, clone RTK2758BiolegendCat\# 400508Anti-mouse Rat IgG2b, κ, PE, clone RTK4530BiolegendCat\# 400608Anti-mouse Rat IgG2a, κ, Alexa Fluor® 488, clone RTK2758BiolegendCat\# 400525Anti-mouse Rat IgG1, κ, PE, clone P3.6.2.8.1eBioscienceCat\# 12-4714-82Anti-mouse anti-ICAM-1, clone YN1/1.7.4BioXcellCat\# BE0020-1, RRID: [AB_1107661](nif-antibody:AB_1107661){#intref0350}Anti-mouse anti-ICAM-2, clone 3C4(mIC2/4)BD bioscienceCat\# 553325Anti-mouse anti-VCAM-1, clone M/K-2.7BioXcellCat\# BE0027, RRID: [AB_1107572](nif-antibody:AB_1107572){#intref0355}Anti-mouse anti-P-selectin, clone RB40.34BD bioscienceCat\# 553742Anti-mouse anti-CD62E, clone 10E9.6BD bioscienceCat\# 553749Anti-mouse anti-CD62L, clone Mel-14BioXcellCat\# BE0021, RRID: [AB_1107665](nif-antibody:AB_1107665){#intref0360}Anti-mouse anti-PSGL-1, clone 4RA10BioXcellCat\# BE0186, RRID: [AB_10950305](nif-antibody:AB_10950305){#intref0365}Anti-mouse anti-CD18, clone M18/2BioXcellCat\# BE0009, RRID: [AB_1107607](nif-antibody:AB_1107607){#intref0370}Anti-mouse anti-CD29, clone KMI6BioXcellCat\# BE0232, RRID: [AB_2687714](nif-antibody:AB_2687714){#intref0375}Anti-mouse anti-CD49d, clone clone PS/2BioXcellCat\# BE0071, RRID: [AB_1107657](nif-antibody:AB_1107657){#intref0380}Anti-mouse anti-CD11a, clone Clone: M17/4BioXcellCat\# BE0006, RRID: [AB_1107578](nif-antibody:AB_1107578){#intref0385}Anti-mouse Rat IgG2a Isotype control, clone 2A3BioXcellCat\# BE0089, RRID: [AB_1107769](nif-antibody:AB_1107769){#intref0390}Anti-mouse Rat IgG1 Isotype control, clone HRPNBioXcellCat\# BE0088, RRID: [AB_1107775](nif-antibody:AB_1107775){#intref0395}Anti-mouse Rat IgG2b Isotype control, clone LTF-2BioXcellCat\# BE0090, RRID: [AB_1107780](nif-antibody:AB_1107780){#intref0400}**Chemicals, Peptides, and Recombinant Proteins**CCR4 antagonist, C 021 dihydrochlorideTocrisCat\# 3581CXCR2 antagonist, SB 265610TocrisCat\# 2724CXCR4 antagonist, AMD 3100 octahydrochlorideTocrisCat\# 3299CellTrace CFSEThermo Fisher ScientificCat\# C34554Cell tracker Deep redThermo Fisher ScientificCat\# C34565Lipopolysaccharides (LPS)SigmaCat\# L4516Tween80SigmaCat\# P4780Dimethyl sulfoxide (DMSO)SigmaCat\# D2650Collagenase IVSigmaCat\# C5138Deoxyribonuclease I (Dnase I)AplicemCat\# A3778DAPIBiolegendCat\# 422801TamoxifenSigmaCat\# T5648TNFαPeprotechCat\# 300-01AIFNγPeprotechCat\# 300-02CXCL12MerckSeronoIn-house production**Critical Commercial Assays**EasySep mouse neutrophil enrichment KitSTEMCELL TechnologiesCat\# 19762EasySep mouse monocyte isolation KitSTEMCELL TechnologiesCat\# 19861EasySep mouse B cell isolation kitSTEMCELL TechnologiesCat\# 19854RNeasy Plus mini KitQIAGEN Hilden GermanyCat\# 74136Human B cell negative selection kitMiltenyi BiotecCat\# 130-091-151**Experimental Models: Cell Lines**BS50 B-ALL cellsRudi W Hendriks, Erasmus MC Rotterdam, the NetherlandsN/AC1498 AML cellsATCCCat\# TIB49NALM-6 human B-ALL cellsATCCCat\# CRL-3273human umbilical vein endothelial cellsUniversity Geneva HospitalN/A**Experimental Models: Organisms/Strains***CD19-cre* miceJackson LaboratoriesCat\# 006785*Lyz2-cre* miceJackson LaboratoriesCat\# 004781*Bmal1*^*flox/flox*^Jackson LaboratoriesCat\# 007668*Cdh5-cre*/ERT2 miceRalf Adams, MPI Münster, GermanyN/AC57BL/6J CD45.1 (B6.SJL-*Ptprc*^*a*^*Pepc*^*b*^/BoyCrl)Charles RiverLy5.1 miceNSG (NOD.Cg-*Prkdc*^*scid*^*IL2rg*^*tm1Wjl*^/SzJ)Charles RiverJAX Cat\# 05557**Oligonucleotides***Nr1d1* Forward GAT AGC TCC CCT TCT TCT GCA TCA TCEurofins GenomicsN/A*Nr1d1* Reverse TTC CAT GGC CAC TTG TAG ACT TCEurofins GenomicsN/A*Sell* Forward GAC GCC TGT CAC AAA CGA AAEurofins GenomicsN/A*Sell* Reverse GCC CGT AAT ACC CTG CAT CAEurofins GenomicsN/A*Cxcl12* Forward CAG AGC CAA CGT CAA GCAEurofins GenomicsN/A*Cxcl12* Reverse AGG TAC TCT TGG ATC CACEurofins GenomicsN/A**Software and Algorithms**GraphPad Prism7Graphpad softwareN/AFlowjo 10.4Flowjo, LLC[www.flowjo.com](http://www.flowjo.com){#intref0405}Becton DickinsonFACSDiva v8.0.1N/AZeissZENN/AImageJ version 1.51n<https://imagej.net>N/Aslidebook version 6Intelligent Imaging Innovations, 3i[www.intelligent-imaging.com](http://www.intelligent-imaging.com){#intref0415}

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Reagents used in this study are available from the commercial sources listed. Further information and requests for other materials should be directed to and will be fulfilled by the Lead Contact, Christoph Scheiermann (<christoph.scheiermann@med.uni-muenchen.de> or <christoph.scheiermann@unige.ch>)

Experiment Model and Subject Details {#sec4.3}
------------------------------------

### Mice {#sec4.3.1}

Male C57BL/6N mice aged 7--8 weeks were purchased from Charles River Laboratories (Sulzfeld, Germany). *Bmal1*^flox/flox^, *Cd19cre*, *Lyz2cre* transgenic mice were purchased from Jackson Laboratories, and crossbred to target B cells and myeloid cells, respectively. *Cdh5-creERT2* mice were obtained as a gift from Ralf Adams (Max-Planck-Institute for Molecular Biomedicine, Münster) via Eloi Montanez (LMU, Munich) and were given intraperitoneal tamoxifen injections for five consecutive days to induce *Cre* recombinase expression. Mice were then used for experiments 2--3 weeks after. NSG and C57BL/6J CD45.1 mice were obtained from Jackson Laboratory and Charles River respectively and bred in a pathogen-free environment. Experimental mice were male and used at 6--12 weeks of age. Mice were maintained in a 12 h light: 12 h dark cycle with *ad libitum* access to food and water. For some experiments, mice were put in cabinets to change the light phase in order to perform experiments with animals on different light schedules at the same time. All animal procedures were in accordance with the German Law of Animal Welfare or the French laws and protocols and approved by the Regierung of Oberbayern or French animal ethics committees, respectively.

### Humans {#sec4.3.2}

Eight healthy volunteers (four males and four females) aged 25-40 years donated blood for human blood counts experiment. Three healthy volunteers aged 26--48 years donated blood for the human B cell transmigration assay. Experiments were approved by the ethics committee of the LMU Munich and the University of Geneva. All volunteers gave written consent to participating in the study.

Method Details {#sec4.4}
--------------

### Flow cytometry {#sec4.4.1}

Mice were anesthetized by inhalation of isoflurane. Blood was collected by bleeding into EDTA-coated capillary tubes. Leukocyte counts were obtained using an IDEXX ProCyte DX cell counter. Erythrocytes were lysed by red blood cell (RBC) lysis buffer (0.8% NH~4~Cl) 2 times, for 5 min each. Abdominal fluid was collected with a syringe by flushing with 5 mL PBS. Spleens were harvested from animals and processed through a cell strainer (40 μm, Thermo Fisher Scientific). Bone marrow cells were harvested from either one femur only or two femurs and two tibias by flushing the bone gently with cold PBS. Lung and liver were first cut into small pieces in DPBS, supplemented with calcium and magnesium (Sigma) and then incubated for 1 h in digestion buffer with collagenase IV (1 mg/ml, C5138, Sigma) and DNase I (0.2 mg/ml, Applichem) at 37°C with gentle agitation. After digestion, cells were filtered through a cell strainer (40 μm, Thermo Fisher Scientific) and resuspended in 5 mL RBC lysis buffer for 5 min. After centrifugation, the supernatant was removed. Leukocytes were resuspended in PBS supplemented with 2% fetal bovine serum (GIBCO) and 2mM EDTA, then stained with fluorescence-conjugated antibodies for 30 min on ice. After washing with PBS, cells were resuspended in DAPI (Biolegend) buffer, and analyzed by flow cytometry using a Gallios Flow Cytometer (Beckman Coulter).

Human blood was collected into EDTA-coated tubes (SARSTEDT, Germany) at 8am, 11am, 3pm, 7pm and 11pm. Human blood was prepared as described above for mouse cells and stained with antibodies at room temperature for 30 min. After washing with PBS, cells were resuspended in DAPI (Biolegend) buffer, and analyzed by flow cytometry using a Gallios Flow Cytometer (Beckman Coulter).

### Functional blocking experiments and induction of inflammation {#sec4.4.2}

To investigate the role of specific pro-migratory molecules in the rhythmic homing process, antibody or antagonist experiments were performed in combination with adoptive transfer assays. Blocking antibodies or chemokine antagonists were diluted into working concentrations (see table below) with PBS or 5% DMSO with 1% Tween80 (Sigma) and injected i.v. or i.p. to recipient mice 2 h before injection of donor cells. Cells were then processed as described above. In order to induce systemic inflammatory conditions, LPS (L4516, Sigma) was injected i.p. (10 mg/kg) to recipient mice at the same time as the injection of blocking antibodies. For CXCR4 *ex vivo* blocking, donor cells were pre-incubated with AMD3100 (300ug/ml) for 1 hour at 37°C in RPMI 1640 (Sigma) plus 10% FCS (Sigma) and stained with CFSE for 20 min.

Working concentration of blocking antibodies and functional blockers.Antibodies or chemicalsVolumemediumInjectionanti-ICAM-1200 μg/mousePBSi.v.anti-ICAM-260 μg/mousePBSi.v.anti-VCAM-1200 μg/mousePBSi.v.anti-P-selectin30 μg/mousePBSi.v.anti-CD62E50 μg/mousePBSi.v.anti-CD62L200 μg/mousePBSi.v.anti-PSGL-1200 μg/mousePBSi.v.anti-CD18200 μg/mousePBSi.v.anti-CD29200 μg/mousePBSi.v.anti-CD49d100 μg/mousePBSi.v.anti-CD11a100 μg/mousePBSi.v.CCR4 antagonist125 μg/mousePBSi.p.CXCR2 antagonist125 μg/mouse5% DMSO with 1% Tween80i.p.CXCR4 antagonist125 μg/mousePBSi.p.

### Adoptive transfer assays {#sec4.4.3}

To investigate the emigration of leukocytes from blood, adoptive transfer experiments were performed and donor cells remaining in blood were measured as a negative indicator of how many cells had migrated into tissues. First, donor cells were obtained from bone marrow and spleen from donor mice. Single cell suspensions were obtained by flushing bone marrow with cold PBS and smashing spleen gently through a cell strainer (40 μm, Thermo Fisher Scientific). Cells were lysed with RBC lysis buffer for 5 min and resuspended in cell incubation buffer (PBS, 0.2%BSA, 2mM EDTA) and counted on a cell counter (ProCyte DX cell counter). 10^7^ bone marrow cells and 10^7^ spleen cells were mixed as donor cells for one recipient mouse. Donor cells were labeled with 1.5 μM CFSE (Thermo Fisher Scientific) or 0.1 μM CellTracker Deep Red dye (Thermo Fisher Scientific) for 20 min at 37°C. In adoptive transfer experiments using donors of different phases, donor cells from two time zones (10^7^ mixed donor cells per time zone) were labeled differently and injected into one recipient. After one hour, blood and organs were harvested from recipient mice and processed as described above for flow cytometry analyses.

In some experiments, injections of an anti-CD45 antibody (clone I3/2.3) were followed by perfusion in order to distinguish between cells adherent to the vascular endothelium or located in the extravascular space. Injection of donor cells was performed as described before. After 56 min, 10 μl anti-CD45 (clone I3/2.3) in 200 μl PBS were injected intravenously to recipient mice. 4 min later, mice were sacrificed using an overdose of isoflurane and perfused with PBS via first the left ventricle and then the right ventricle in order to perfuse the whole body and the lung, respectively.

### Cell isolation and Q-PCR {#sec4.4.4}

Spleen B cells were purified from *Cd19*cre *Bmal1*^flox/flox^ and littermate control mice using the EasySep mouse B cell isolation kit (STEMCELL Technologies) according to the manufacturer's protocol, and purity (\> 92%) was accessed by flow cytometry. Bone marrow monocytes and neutrophils were purified from *Lyz2*cre *Bmal1*^*flox/flox*^ and littermate control mice using a monocyte isolation kit and a neutrophil enrichment kit (STEMCELL Technologies), respectively. Purity of monocytes was about \> 93% and of neutrophils around \> 82%.

RNA was extracted from isolated cells using the RNeasy Plus mini Kit (QIAGEN, Hilden Germany) following the manufacturers' instructions. Total organ RNA extraction was performed with TRIzol (QIAGEN). Tissues were homogenized with a homogenizer (SpeedMill PLUS, Analytic Jena). RNA clean-up was performed using the RNeasy Plus mini Kit (QIAGEN, Hilden Germany) and following the manufacturers' instructions. RNA samples were analyzed using a NanoDrop2000 (Thermo Scientific) to determine RNA concentration and quality. RNA was stored at −80°C. For reverse transcription, 150-200 ng RNA for isolated cells and 2 μg RNA for organs were used with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). cDNA samples were stored at −20°C prior to use in quantitative PCR (Q-PCR). Q-PCR was performed with a StepOnePlus Real-Time PCR System (Applied Biosystems) in 96-well plates with SYBR green compatible primers at 60°C. Duplicates or triplicates were performed for each Q-PCR sample. The total reaction volume was 10 μl, containing 5 μl SYBR green, 1 μl primer mix (5 μM), 2 μl H~2~O and 1.5 ng cDNA for cells or 20ng cDNA for organs. Gene expression levels were normalized to the housekeeping gene *Gapdh*.

### Immunofluorescence staining {#sec4.4.5}

To measure adhesion molecule expression levels on endothelial cells, organs were placed in OCT (TissueTec), frozen at −80°C and sectioned with a thickness of 10 μm on a cryostat (Leica). Sections were fixed with cold methanol for 10 min at room temperature, incubated in PBS containing Triton X-100 (0.5%), and normal goat serum (20%). Sections were stained with antibodies and incubated at 4°C overnight. Images were obtained using a Zeiss Axio Examiner.D1 microscope equipped with 405, 488, 563, and 655 nm LED excitation light sources. All quantifications were performed using mask analyses with the Zeiss software based on PECAM-1 expression. Quantifying expression of other fluorescent channels within this mask was then performed. Areas smaller than 10 μm^2^ were excluded from analysis to minimize non-specific signals. Protein expression levels were presented as mean fluorescence intensity (MFI) within the mask area and after subtraction of the respective isotype controls. Levels of expression below the isotype threshold for all assessed time-points or the majority of time-points was termed no or low expression, respectively.

For visualizing the precise localization of injected donor cells in adoptive transfer assays, mice were injected intravenously with donor cells and additionally with 40 μl of an anti-PECAM-1 antibody (clone 390) in 160 μl PBS prior to organ harvest. 5 min later, mice were anesthetized by inhalation of isoflurane, and perfused with PBS. Organs were put in OCT and frozen at −80°C. Images were obtained using a Zeiss Axio Examiner.Z1 confocal spinning disk microscope equipped with 405, 488, 561, and 640 nm laser sources using both tissue sections and whole mounts of organs. Quantification was performed using ImageJ (version 1.51n) and slidebook (version 6, Intelligent Imaging Innovations, 3i).

### Leukemic models {#sec4.4.6}

To assess leukemic engraftment, adult NSG or C57BL/6J CD45.1 mice (6--10 weeks old) were injected retro-orbitally with 5 x10^6^ leukemic cells at ZT1 or ZT13. Leukemic development was monitored on blood samples obtained by bleeding into Heparin-coated capillary tubes. Leukocyte counts were obtained using an IDEXX ProCyte DX cell counter and percentage of leukemic cells was determined by flow cytometry. Samples from mice engrafted with BS50 and C1498 leukemic cells were stained with anti-mouse CD45.1-PE-CF594 (clone A20, BD Biosciences) and anti-mouse CD45.2-AF700 (clone 104, Biolegend), while samples from NSG mice engrafted with NALM6 were stained with anti-human CD45-PE (BD PharMingen) and anti-mouse CD45-eFluor780 (clone 30-F11, eBiosciences). RBC were lysed using BD FACs Lysis buffer and samples were analyzed using a Fortessa (Becton Dickinson) flow cytometer.

### Transmigration assay of human B cells {#sec4.4.7}

Non-synchronized HUVECs were cultured in chamber slides for 2--3 days and then treated for 24 h using a chronic activation protocol ([@bib5]). The first stage of activation consisted of overnight TNFα (1000 U/ml) and IFNγ (500 U/ml) stimulation. B cells (80%--95%) were purified from EDTA-treated blood collected from healthy donors using a negative selection kit (Miltenyi Biotec). The flow assay set-up consisted of a heated microscope chamber (37°C) and a calibrated pump where flow was generated over attached HUVEC monolayers by perfusing wash buffer, or a B cell suspension. The flow rate was set to represent small venules/capillaries (0.05 Pa). Assays were initiated with a second stage HUVEC activation, where CXCL12 (1 μM) was perfused over the monolayer for 15 min (step 1). Wash-buffer was then pumped for 10 min over the HUVECs to remove any unbound CXCL12 before the B cell suspension was perfused over the HUVECs for 5 min (step 2) followed by 90 min of wash-buffer (step 3). Throughout steps 2--3, images of the captured B cells were taken using phase-contrast microscopy, and a high-resolution camera. Individual images were recorded every 30 s and compiled into short movie sequences, allowing analysis of individual B cells over large areas. B cells adherent to the surface of the HUVECs showed a phase-white appearance, whereas those that had transmigrated showed a phase-black appearance. Adhesion events were recorded as the total of number of cells per unit field (mm^2^). Transmigration events were presented as a percentage of total B cells captured from flow per unit field. All experiments were carried out using quadruplicate fields and presented as a mean value with + standard error measurements (±SEM).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Data was analyzed using Prism 7 (GraphPad) and presented as mean ± standard error of mean (SEM). A p value \< 0.05 was considered as statistically significant. Comparisons between two groups were performed using unpaired Student's t test. One-way ANOVA analysis followed by Tukey's multiple comparison test was used for multiple group comparison. One-way ANOVA analysis followed by Dunnett's test was used for comparison between control and treatment groups. Human WBC counts were analyzed by repeated-measures one-way ANOVA. Mann-Whitney non-parametric analyses were performed for non-Gaussian distribution patterns in leukemia tumor burden.

Data and Software Availability {#sec4.6}
------------------------------

Data are available upon request.

Supplemental information {#app2}
========================

Document S1. Figures S1--S7Table S1. Diurnal Expression of Endothelial Cell-Adhesion Molecules, Related to Figure 2Expression data are normalized to peak levels (1,00), after subtraction of isotype controls. n.s. not significant; n.e. not expressed, due to higher isotype than molecule expression levels for all or most time points; Max MFI, expression at peak times.Table S2. Diurnal Expression of Leukocyte Pro-migratory Factors, Related to Figure 3Expression data are normalized to peak levels (1,00). n.s. not significant; n.e. not expressed, due to higher isotype than molecule expression levels for all or most time points; Max MFI, expression at peak times.Document S2. Article plus Supplemental Information
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